vendredi 24 juillet 2015

Onco Actu du 24 juillet 2015

(pour info : la parution de ce bulletin s'interrompt pendant 4 semaines)

1. Biologie

Using CRISPR to investigate pancreatic cancer [Scope Blog]

5. Traitements

Oestrogen-suppressing drugs substantially reduce breast cancer deaths [The Institute of Cancer Research]

Hitting the self-destruct switch – standing up to womb cancer with PARP inhibitors [Cancer Research UK]

Osteoporosis drug could benefit postmenopausal women with breast cancer [Cancer Research UK]

A Systemic Immunomodulator IMM-101 Extends Survival and Maintains Quality of Life in the IMAGE1 Study [ESMO]

Cheap osteoporosis drug could prevent a sixth of breast cancer deaths [The Guardian]

5.2 Pharma

Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma [Amgen]

European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe [BMS]

5.2.1 Pharma - Partenariats

Merck extends Ablynx immuno-oncology relationship with heavily backloaded €4B deal [Fierce Biotech]

5.3 Traitements - FDA, EMA,...

Sunesis Pharmaceuticals Announces Regulatory Update [Sunesis]

FDA seeks more clinical evidence on Sunesis Pharma cancer drug [Reuters]

5.4 Traitements - Economie

Doctors Press For Action To Lower 'Unsustainable' Prices For Cancer Drugs [NPR]

115 Doctors Propose This Solution For Terrifying Cancer Drug Prices [Forbes]

6. Lutte contre les cancers

Timothy Caulfield: Genetics and personalized medicine—where’s the revolution? [BMJ Blogs]

Chemotherapy May Worsen End-of-Life Quality, Study Finds [NY Times]

6.6 Publications

The UK Recommends ORCID [ORCID]

6.7.3 DMP

The tragedy of the electronic health record [The Pharos]

6.9 Controverses

Spilling the beans [The Economist]